Table 1 Patient characteristics
Group | Gender | Age | Diagnosis | Age at diagnosis | IS |
|---|---|---|---|---|---|
1 | f | 9 | CD | 3 | Sirolimus 0.1 mg/kg/day (10.4 ng/ml blood level) |
1 | m | 14 | UC | 11 | Vedolizumab 300 mg/8 weeks |
1 | m | 17 | UC | 15 | Adalimumab 40 mg/week (11.57 μg/ml blood level) |
1 | f | 12 | CD | 8 | Adalimumab 40 mg/week (10.35 μg/ml blood level) |
1 | m | 16 | CD | 3 | Adalimumab 40 mg/2 weeks (6.5 μg/ml blood level) |
1 | m | 14 | UC | 12 | Adalimumab 40 mg/week (12.35 μg/ml blood level) Tacrolimus 0.12 mg/kg/day (2.6 ng/ml blood level) AZA 1.0 mg/kg/day |
1 | f | 11 | UC | 10 | Infliximab 5 mg/kg/4 weeks (4.66 μg/ml blood level) |
1 | f | 18 | UC | 17 | Vedolizumab 300 mg/8 weeks AZA 2.6 mg/kg/day Sirolimus 0.18 mg/kg/day (8.8 ng/ml blood level) Prednisolone 0.5 mg/kg/day |
1 | f | 15 | UC | 10 | Adalimumab 40 mg/4 weeks (6.5 μg/ml blood level) |
1 | m | 5 | CD | 3 | Infliximab 10 mg/kg/4 weeks (0.5 μg/ml blood level) Tacrolimus 0.19 mg/kg/day (30.9 ng/ml blood level) |
1 | f | 14 | CD | 13 | Infliximab 5 mg/kg/4 weeks (3.36 μg/ml blood level) |
1 | m | 14 | CD | 13 | Infliximab 5 mg/kg/6 weeks (1.56 μg/ml blood level) AZA 2.1 mg/kg/d |
1 | m | 9 | UC | 6 | Infliximab 5 mg/kg/6–8 weeks (1.03 μg/ml blood level) AZA 2.2 mg/kg/day |
1 | f | 10 | UC | 5 | Vedolizumab 250 mg/8 weeks |
1 | m | 12 | CD | 12 | Infliximab 5 mg/kg/8 weeks (0.94 μg/ml blood level) |
1 | m | 11 | CD | 4 | Golimumab 50 mg/4 weeks (8.5 μg/ml blood level) |
1 | m | 15 | CD | 13 | Infliximab 5 mg/kg/4 weeks (14.2 μg/ml blood level) |
2 | f | 10 | CD | 8 | AZA 2.3 mg/kg/day |
2 | f | 9 | UC | 1 | AZA 2.2 mg/kg/day |
2 | m | 18 | CD | 16 | AZA 1.9 mg/kg/day |
2 | f | 17 | CD | 3 | AZA 1.9 mg/kg/day |
2 | f | 13 | AIH | 4 | AZA 1 mg/kg/day |
2 | m | 17 | AIH | 10 | AZA 1.7 mg/kg/day |
2 | f | 16 | AIH | 12 | AZA 1.1 mg/kg/day |
2 | f | 9 | UC | 5 | Tacrolimus 0.23 mg/kg/day (4.5 ng/ml blood level) |
3 | f | 13 | CD | 12 | No IS |
3 | m | 15 | CD | 3 | No IS |
3 | f | 3 | CD | 3 | No IS |
3 | m | 14 | UC | 2 | No IS |
3 | f | 15 | UC | 10 | No IS |
3 | m | 12 | CD | 12 | No IS |